The Times Australia
The Times World News

.

the rise and fall of COVID convalescent plasma therapy

  • Written by Andrew McLachlan, Head of School and Dean of Pharmacy, University of Sydney
the rise and fall of COVID convalescent plasma therapy

Early in the pandemic, scientists thought “convalescent plasma” might be a way to treat COVID-19.

By giving patients the plasma of people who had recovered (or convalesced) from COVID-19, the idea was this antibody-rich infusion would help their immune systems fight infection. It’s a strategy tried, with various degrees of success, for other infectious diseases, including Ebola.

But growing evidence, including an international study published this week[1], shows convalescent plasma does not save lives of people critically ill with COVID-19. The researchers concluded the therapy was “futile”.

Read more: Coronavirus: what is plasma therapy?[2]

What is convalescent plasma?

Convalescent plasma[3] is a blood product containing antibodies against an infectious pathogen (such as SARS-CoV-2, the coronavirus that causes COVID-19). It comes from blood collected from people who have recovered from the infectious disease.

Scientists use a process called apheresis[4] to separate the different blood components[5]. Red and white cells, and platelets are removed leaving plasma, which is rich in antibodies.

The story of convalescent plasma therapy (or serum therapy) originates in the 1890s. This is when physician Emil von Behring[6] infected horses with the bacteria that causes diphtheria.

Once the horses recovered, Behring collected their antibody-rich blood to treat humans[7] with the disease. This led to him being awarded the first Nobel prize in physiology or medicine, in 1901.

Why has convalescent plasma been used to treat COVID?

Convalescent plasma has been used to treat infectious diseases[8] for over a century. These include: scarlet fever, pneumonia, tetanus, diphtheria, mumps and chickenpox.

More recently, convalescent plasma has been investigated as a treatment[9] for SARS (severe acute respiratory syndrome), MERS (Middle East respiratory syndrome) and Ebola.

So early in the pandemic, researchers hoped convalescent plasma could be used to treat COVID-19[10] too.

Read more: I'm a lung doctor testing the blood plasma from COVID-19 survivors as a treatment for the sick – a century-old idea that could be a fast track to treatment[11]

Initial studies and some clinical trials[12] were promising. This led to the widespread use[13] of convalescent plasma for patients with COVID-19 in the United States, a decision supported by the Food and Drug Administration[14].

By May this year more than 100 clinical trials[15] had been conducted with convalescent plasma in people with COVID-19; about one-third of these studies had finished or were stopped early.

Earlier this year, the results of the United Kingdom’s landmark RECOVERY trial[16] were reported. This investigated convalescent plasma therapy (compared to usual supportive care) in more than 10,000 people hospitalised with COVID-19.

Treatment did not reduce the risk of death (24% in both groups), with no difference in the number of patients who recovered (66% discharged from hospital in both groups) or who got worse (29% needed mechanical ventilation to support breathing in both groups).

So for people admitted to hospital with COVID-19, the researchers concluded convalescent plasma offered no benefit.

A Cochrane review[17], which was updated in May this year and evaluated all available trials, confirmed these results. These trials involved more than 40,000 people with moderate-to-severe COVID-19 who received convalescent plasma.

The review found the treatment had no effect on the risk of dying from COVID-19, did not reduce the risk of requiring hospitalisation nor the need for a ventilator to assist breathing when compared to placebo or standard care.

In Australia, the National COVID-19 Clinical Evidence Taskforce[18] does not recommend using convalescent plasma in people with COVID-19, unless it is in a clinical trial.

Read more: Here's what happens when you’re hospitalised with COVID[19]

What’s the latest news?

The results of the trial reported this week[20] come from a major clinical trial involving about 2,000 hospitalised patients with moderate-to-severe COVID-19.

Patients were randomised to received convalescent plasma or usual care. All patients had access to other supportive medicines used in critically ill hospitalised people with COVID, such as dexamethasone[21] and remdesivir[22].

The international team[23] of investigators included those from Australia, Canada, UK and US.

Although the results and detailed analysis were published this week, the trial was halted in January[24]. This is when the trial committee reviewed the interim results and reported “convalescent plasma was unlikely to be of benefit for patients with COVID-19 who require organ support in an intensive care unit”. So continuing the trial was considered futile.

Convalescent plasma treatment did not reduce the risk of death in hospital over the month after treatment (37.3% convalescent plasma treated, 38.4% usual care, not treated with convalescent plasma). The median number of days without the need for organ support (such as a mechanical ventilator or cardiac support) was 14 days in both groups. Serious adverse events were reported in 3.0% of people treated with convalescent plasma and only 1.3% in the usual care group.

Taken together, the weight of evidence now clearly demonstrates convalescent plasma is not a treatment option for people with mild, moderate or even severe COVID-19.

Where next for COVID-19 treatments?

While vaccinations remain the major strategy[25] to prevent COVID-19, attention is now turning to some emerging and promising treatments to prevent COVID-19 worsening.

These include emerging antiviral treatments that may be used early in the disease, including monoclonal antibodies such as sotrovimab[26] and AZD7442[27]. Then there are potential oral antiviral medicines, such as molnupiravir[28] and PF-07321332[29].

Read more: Take-at-home COVID drug molnupiravir may be on its way — but vaccination is still our first line of defence[30]

References

  1. ^ study published this week (jamanetwork.com)
  2. ^ Coronavirus: what is plasma therapy? (theconversation.com)
  3. ^ Convalescent plasma (onlinelibrary.wiley.com)
  4. ^ apheresis (www.petermac.org)
  5. ^ different blood components (theconversation.com)
  6. ^ Emil von Behring (www.nobelprize.org)
  7. ^ antibody-rich blood to treat humans (theconversation.com)
  8. ^ treat infectious diseases (www.ncbi.nlm.nih.gov)
  9. ^ treatment (academic.oup.com)
  10. ^ used to treat COVID-19 (theconversation.com)
  11. ^ I'm a lung doctor testing the blood plasma from COVID-19 survivors as a treatment for the sick – a century-old idea that could be a fast track to treatment (theconversation.com)
  12. ^ some clinical trials (pubmed.ncbi.nlm.nih.gov)
  13. ^ widespread use (onlinelibrary.wiley.com)
  14. ^ Food and Drug Administration (www.fda.gov)
  15. ^ more than 100 clinical trials (pubmed.ncbi.nlm.nih.gov)
  16. ^ RECOVERY trial (www.thelancet.com)
  17. ^ A Cochrane review (pubmed.ncbi.nlm.nih.gov)
  18. ^ National COVID-19 Clinical Evidence Taskforce (app.magicapp.org)
  19. ^ Here's what happens when you’re hospitalised with COVID (theconversation.com)
  20. ^ trial reported this week (jamanetwork.com)
  21. ^ dexamethasone (theconversation.com)
  22. ^ remdesivir (theconversation.com)
  23. ^ international team (www.remapcap.org)
  24. ^ trial was halted in January (www.remapcap.org)
  25. ^ major strategy (theconversation.com)
  26. ^ sotrovimab (theconversation.com)
  27. ^ AZD7442 (www.astrazeneca.com)
  28. ^ molnupiravir (theconversation.com)
  29. ^ PF-07321332 (www.tga.gov.au)
  30. ^ Take-at-home COVID drug molnupiravir may be on its way — but vaccination is still our first line of defence (theconversation.com)

Read more https://theconversation.com/curing-with-blood-the-rise-and-fall-of-covid-convalescent-plasma-therapy-169347

Times Magazine

Headless CMS in Digital Twins and 3D Product Experiences

Image by freepik As the metaverse becomes more advanced and accessible, it's clear that multiple sectors will use digital twins and 3D product experiences to visualize, connect, and streamline efforts better. A digital twin is a virtual replica of ...

The Decline of Hyper-Casual: How Mid-Core Mobile Games Took Over in 2025

In recent years, the mobile gaming landscape has undergone a significant transformation, with mid-core mobile games emerging as the dominant force in app stores by 2025. This shift is underpinned by changing user habits and evolving monetization tr...

Understanding ITIL 4 and PRINCE2 Project Management Synergy

Key Highlights ITIL 4 focuses on IT service management, emphasising continual improvement and value creation through modern digital transformation approaches. PRINCE2 project management supports systematic planning and execution of projects wit...

What AI Adoption Means for the Future of Workplace Risk Management

Image by freepik As industrial operations become more complex and fast-paced, the risks faced by workers and employers alike continue to grow. Traditional safety models—reliant on manual oversight, reactive investigations, and standardised checklist...

From Beach Bops to Alpine Anthems: Your Sonos Survival Guide for a Long Weekend Escape

Alright, fellow adventurers and relaxation enthusiasts! So, you've packed your bags, charged your devices, and mentally prepared for that glorious King's Birthday long weekend. But hold on, are you really ready? Because a true long weekend warrior kn...

Effective Commercial Pest Control Solutions for a Safer Workplace

Keeping a workplace clean, safe, and free from pests is essential for maintaining productivity, protecting employee health, and upholding a company's reputation. Pests pose health risks, can cause structural damage, and can lead to serious legal an...

The Times Features

The Role of Your GP in Creating a Chronic Disease Management Plan That Works

Living with a long-term condition, whether that is diabetes, asthma, arthritis or heart disease, means making hundreds of small decisions every day. You plan your diet against m...

Troubleshooting Flickering Lights: A Comprehensive Guide for Homeowners

Image by rawpixel.com on Freepik Effectively addressing flickering lights in your home is more than just a matter of convenience; it's a pivotal aspect of both home safety and en...

My shins hurt after running. Could it be shin splints?

If you’ve started running for the first time, started again after a break, or your workout is more intense, you might have felt it. A dull, nagging ache down your shins after...

Metal Roof Replacement Cost Per Square Metre in 2025: A Comprehensive Guide for Australian Homeowners

In recent years, the trend of installing metal roofs has surged across Australia. With their reputation for being both robust and visually appealing, it's easy to understand thei...

Why You’re Always Adjusting Your Bra — and What to Do Instead

Image by freepik It starts with a gentle tug, then a subtle shift, and before you know it, you're adjusting your bra again — in the middle of work, at dinner, even on the couch. I...

How to Tell If Your Eyes Are Working Harder Than They Should Be

Image by freepik Most of us take our vision for granted—until it starts to let us down. Whether it's squinting at your phone, rubbing your eyes at the end of the day, or feeling ...